Lentivirus-mediated gene transfer in hematopoietic stem cells is impaired in SHIV-infected, ART-treated nonhuman primates

Molecular Therapy

Volumn 23, Issue 5, 2015, Pages 943-951

  Younan, Patrick M ^a   Peterson, Christopher W ^a   Polacino, Patricia ^b   Kowalski, John P ^a   Obenza, Willimark ^a   Miller, Hannah W ^a   Milless, Brian P ^a   Gafken, Phil ^a   Derosa, Stephen C ^a   Hu, Shiu Lok ^a,c   Kiem, Hans Peter ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Washington National Primate Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; EMTRICITABINE; RALTEGRAVIR; TENOFOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34 SELECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENTIVIRINAE; LYMPHOCYTE DIFFERENTIATION; MACACA NEMESTRINA; MEMORY T LYMPHOCYTE; NONHUMAN; PROTEIN EXPRESSION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE SUBPOPULATION; VIRAL GENE DELIVERY SYSTEM; VIREMIA; WHOLE BODY RADIATION; ANIMAL; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; METABOLISM; RADIATION RESPONSE; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSGENE; TRANSPLANTATION CONDITIONING; VIROLOGY; VIRUS LOAD;

ANIMALIA; LENTIVIRUS; MACACA; PRIMATES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; IMMUNOPHENOTYPING; LENTIVIRUS; LYMPHOCYTE COUNT; MACACA NEMESTRINA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTE SUBSETS; TRANSDUCTION, GENETIC; TRANSGENES; TRANSPLANTATION CONDITIONING; VIRAL LOAD;

EID: 84929045746     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.19     Document Type: Article

References (50)

1. Little RF and Dunleavy K. (2013). Update on the treatment of HIV-associated hematologic malignancies. Hematology Am Soc Hematol Educ Program 2013: 382-388
2. Chao C, Xu, L, Abrams D, Leyden W, Horberg M, Towner W, et al. (2010). Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS 24: 1765-1770
3. Jacobson CA and Abramson JS. (2012). HIV-associated Hodgkin's lymphoma: prognosis and therapy in the era of cART. Adv Hematol 2012: 507257
4. Suneja G, Shiels MS, Angulo R, Copeland GE, Gonsalves L, Hakenewerth AM, et al. (2014). Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol 32: 2344-2350
5. Hütter G and Zaia JA. (2011). Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol 163: 284-295
6. Younan P, Kowalski J and Kiem HP. (2013). Genetic modification of hematopoietic stem cells as a therapy for HIV/AIDS. Viruses 5: 2946-2962
7. Hütter G and Thiel E. (2011). Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS 25: 273-274
8. DiGiusto DL, Stan R, Krishnan A, Li, H, Rossi JJ and Zaia JA. (2013). Development of hematopoietic stem cell based gene therapy for HIV-1 infection: considerations for proof of concept studies and translation to standard medical practice. Viruses 5: 2898-2919
9. DiGiusto DL, Krishnan A, Li, L, Li, H, Li, S, Rao A, et al. (2010). RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2: 36ra43
10. Hütter G and Ganepola S. (2011). Eradication of HIV by transplantation of CCR5- deficient hematopoietic stem cells. Scientific World Journal 11: 1068-1076
11. Armijo E, Soto C and Davis BR. (2014). HIV/AIDS: modified stem cells in the spotlight. Cell Mol Life Sci 71: 2641-2649
12. Zaia JA and Forman SJ. (2013). Transplantation in HIV-infected subjects: is cure possible?. Hematology Am Soc Hematol Educ Program 2013: 389-393
13. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al. (2009). Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360: 692-698
14. Henrich TJ, Hu, Z, Li, JZ, Sciaranghella G, Busch MP, Keating SM, et al. (2013). Long- term reduction in peripheral blood HIV type 1 reservoirs following reducedintensity conditioning allogeneic stem cell transplantation. J Infect Dis 207: 1694-1702
15. Younan P, Kowalski J and Kiem HP. (2014). Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure?. Mol Ther 22: 257-264
16. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. (2014). Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370: 901-910
17. Bovolenta C, Porcellini S and Alberici L. (2013). Therapeutic genes for anti-HIV/AIDS gene therapy. Curr Pharm Biotechnol 14: 488-500
18. Kiem HP, Jerome KR, Deeks SG and McCune JM. (2012). Hematopoieticstem- cell-based gene therapy for HIV disease. Cell Stem Cell 10: 137-147
19. Warnock JN, Daigre C and Al-Rubeai M. (2011). Introduction to viral vectors. Methods Mol Biol 737: 1-25
20. Beard BC, Dickerson D, Beebe K, Gooch C, Fletcher J, Okbinoglu T, et al. (2007). Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther 15: 1356-1365
21. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, et al. (2004). Retroviral DNA integration: ASLV HIV and MLV show distinct target site preferences. PLoS Biol 2: E234
22. Trobridge GD, Allen J, Peterson L, Ironside C, Russell DW and Kiem HP. (2009). Foamy and lentiviral vectors transduce canine long-term repopulating cells at similar efficiency. Hum Gene Ther 20: 519-523
23. Kiem HP, Wu, RA, Sun G, von Laer D, Rossi JJ and Trobridge GD. (2010). Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther 17: 37-49
24. Trobridge GD, Horn PA, Beard BC and Kiem HP. (2012). Large animal models for foamy virus vector gene therapy. Viruses 4: 3572-3588
25. Younan PM, Polacino P, Kowalski JP, Peterson CW, Maurice NJ, Williams NP, et al. (2013). Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 122: 179-187
26. Mavigner M, Watkins B, Lawson B, Lee ST, Chahroudi A, Kean L, et al. (2014). Persistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant. PLoS Pathog 10: e1004406
27. Cillo AR, Krishnan A, Mitsuyasu RT, McMahon DK, Li, S, Rossi JJ, et al. (2013). Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr 63: 438-441
28. Beard BC, Trobridge GD, Ironside C, McCune JS, Adair JE and Kiem HP. (2010). Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest 120: 2345-2354
29. Watts KL, Beard BC, Wood BL, Trobridge GD, Humphries RK, Adams AB, et al. (2014). No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model. Exp Hematol 42: 497-504
30. Trobridge GD, Wu, RA, Beard BC, Chiu SY, Muñoz NM, von Laer D, et al. (2009). Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One 4: e7693
31. Anderson PL, Kakuda TN and Lichtenstein KA. (2004). The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 38: 743-753
32. Robbins BL, Srinivas RV, Kim C, Bischofberger N and Fridland A. (1998). Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl) adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 42: 612-617
33. Wang LH, Begley J, Feng J, Quinn J and Rousseau F. (2002). Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing. The XIV International AIDS Conference International AIDS Society. http://www. iasociety.org/Default.aspx?pageId=11&abstractId=2431 (Abstract # TuPeB4546) (abstract
34. Hawkins T, Veikley W, St Claire R, Hey A, Guyer B and Kearney BP. (2004). Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regimens. Program and Abstracts of the 5th International Worksop on Clinical Pharmacology of HIV Therapy April 1-3, 2004, Rome Italy Abstract #2.4 (abstract
35. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, et al. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816
36. Yuan J, Wang J, Crain K, Fearns C, Kim KA, Hua KL, et al. (2012). Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment. Mol Ther 20: 849-859
37. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, et al. (2008). Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82: 12449-12463
38. Ho, O, Larsen K, Polacino P, Li, Y, Anderson D, Song R, et al. (2009). Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus. Retrovirology 6: 65
39. O'Connor BP, Cascalho M and Noelle RJ. (2002). Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J Exp Med 195: 737-745
40. Wightman F, Solomon A, Khoury G, Green JA, Gray L, Gorry PR, et al. (2010). Both CD31(+) and CD31-?naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 202: 1738-1748
41. Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, et al. (2014). HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345: 570-573
42. Maldarelli F, Wu, X, Su, L, Simonetti FR, Shao W, Hill S, et al. (2014). HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345: 179-183
43. Beard BC, Adair JE, Trobridge GD and Kiem HP. (2014). High-throughput genomic mapping of vector integration sites in gene therapy studies. Methods Mol Biol 1185: 321-344
44. Peterson CW, Younan P, Polacino PS, Maurice NJ, Miller HW, Prlic M, et al. (2013). Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection. J Med Primatol 42: 237-246
45. Trobridge GD, Beard BC, Gooch C, Wohlfahrt M, Olsen P, Fletcher J, et al. (2008). Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV- based lentiviral vectors. Blood 111: 5537-5543
46. Li, Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, et al. (2008). Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 82: 638-651
47. Sun L, Li, H, Willson K, Breidinger S, Rizk ML, Wenning L, et al. (2012). Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial. Anal Chem 84: 8614-8621
48. King T, Bushman L, Kiser J, Anderson PL, Ray M, Delahunty T, et al. (2006). Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci 843: 147-156
49. Polacino P, Cleveland B, Zhu Y, Kimata JT, Overbaugh J, Anderson D, et al. (2007). Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge. J Med Primatol 36: 254-265
50. Butler SL, Johnson EP and Bushman FD. (2002). Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 76: 3739-3747